3.43  -0.03 (-0.87%)		10-04 16:00
Open: 3.6 High: 3.73 Volume: 10,876		Pre. Close: 3.46 Low: 3.41 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	4.41	1-year :	4.88
Resists	First :	3.78	Second :	4.17
Pivot price	3.59
Supports	First :	3.14	Second :	2.61
MAs	MA(5) :	3.47	MA(20) :	3.6
	MA(100) :	4.18	MA(250) :	6.15
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	31	D(3) :	31.4
RSI	RSI(14): 45
52-week	High :	22.35	Low :	3.14

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PALI ] has closed above bottom band by 34.5%. Bollinger Bands are 3.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	3.73 - 3.75	3.75 - 3.77
Low:	3.36 - 3.38	3.38 - 3.4
Close:	3.39 - 3.42	3.42 - 3.46

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

Thu, 26 Sep 2024
Palisade submits CTA for PDE4 inhibitor prodrug for ulcerative colitis - BioWorld Online

Wed, 25 Sep 2024
PALI - Palisade Bio, Inc. Latest Stock News & Market Updates - StockTitan

Wed, 25 Sep 2024
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan

Wed, 25 Sep 2024
Palisade Bio Provides Update on Progress Toward Launch of - GlobeNewswire

Mon, 16 Sep 2024
Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies - StockTitan

Mon, 16 Sep 2024
Palisade Bio Launches New Corporate Branding and Reiterates - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	1 (M)
Shares Float	1 (M)
Held by Insiders	2.2 (%)
Held by Institutions	2.8 (%)
Shares Short	56 (K)
Shares Short P.Month	60 (K)

EPS	-18.57
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	10.28
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-58.6 %
Return on Equity (ttm)	-110.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-12.37
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-8 (M)

PE Ratio	-0.19
PEG Ratio	0
Price to Book value	0.33
Price to Sales	0
Price to Cash Flow	-0.34

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.